Description
Prostate Cancer Metabolism: From Biochemistry to Therapeutics shows the peculiarities of prostate cancer metabolism, emphasizing the targetable aspects - that have not been considered in conventional treatment protocols. The book specifically addresses treatment of the castration-resistant stage of prostate cancer proposing many repurposed drugs and nutraceuticals to complement, not replace, standard therapies. The large body of evidence supporting these concepts makes them deserving of further research and well-designed clinical trials. It discusses lipid, cholesterol, glutamine, and glucose metabolisms and their impact on prostate cancer. Additionally, it explains how current established drugs can be repurposed to improve treatment outcomes. The concepts set out in the book, that deal with cancer at the cellular/molecular level, help identify new avenues of research and treatments to pursue that do not affect well-being whilst offer consistent benefits. Since most practicing physicians have not studied basic biochemistry since medical school, each chapter begins with a brief review of the topic to facilitate an understanding of the metabolically-oriented approach to targeting prostate cancer. Conventional treatments are not discussed here since they are covered in textbooks and specialized updates that abound in the medical literature. It is a valuable resource for cancer researchers, oncologists, clinicians and members of biomedical field who want to learn more about prostate cancer metabolism and how to apply recent findings in the field to bedside.
About the Author
Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master's in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new "triple-edged cancer treatment". Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma. Fatima Baltazar holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (UK, 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima's main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitro and in vivo cancer models. Fatima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications. Research in Dr. Fliegel's laboratory investigates membrane proteins' function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work is funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).
Book Information
ISBN 9780323905282
Author Tomas Koltai
Format Paperback
Page Count 416
Imprint Academic Press Inc
Publisher Elsevier Science & Technology
Weight(grams) 860g
About the Author
Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master's in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new "triple-edged cancer treatment". Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma. Fatima Baltazar holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (UK, 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima's main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitro and in vivo cancer models. Fatima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications. Research in Dr. Fliegel's laboratory investigates membrane proteins' function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work is funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).
Book Information
ISBN 9780323905282
Author Tomas Koltai
Format Paperback
Page Count 416
Imprint Academic Press Inc
Publisher Elsevier Science & Technology
Weight(grams) 860g
